Juno Bio raises $3.8 million and opens Oakland women’s health lab

Juno Bio has raised $3.8 million and opened a sequencing lab in Oakland, California, as it tries to move vaginal microbiome testing from consumer wellness into clinical use. The UK-founded women’s health company said the facility is its first lab built for women’s health, with testing processed in-house under CLIA certification.

The round included Ada Ventures, Artesian, Entrepreneur First and Illumina Accelerator. Juno Bio did not disclose its valuation, the round structure or how long the capital is expected to fund operations.

Juno Bio uses next-generation sequencing to analyze vaginal microbiome samples, with the company positioning the product as a more detailed alternative to conventional tests that look for a narrower set of pathogens. Its new vaginal microbiome and STI test analyzes about 10,000 bacteria and fungi, along with four common sexually transmitted infections, according to the company.

The company says the test is intended to support clinical review for recurrent infections, fertility-related concerns, peri- and menopausal symptoms, and other vaginal health issues that can be difficult to diagnose. Juno Bio says the data may help identify microbes linked to co-infections, subclinical conditions and broader microbiome patterns when interpreted alongside symptoms and clinician review.

Juno Bio has sold more than 20,000 tests since launching its first wellness product, according to the company. It said it has since expanded into a clinical platform with pharmaceutical R&D partnerships, telehealth and pharmacy integrations, its own lab operations, and a network of medical advisers.

One of those advisers is Anna Powell, MD, of Johns Hopkins, who specializes in reproductive infectious disease and vulvovaginal disorders. Powell said, according to Juno Bio, that vaginal microbiome testing could change how clinicians understand and manage vaginal health, while noting that the field is still developing and that microbiome-informed care would complement existing diagnostic approaches.

Founder and CEO Hana Janebdar said the company has spent the past five years building its data repository, clinical infrastructure and research partnerships. Juno Bio says it has built one of the largest repositories of vaginal microbiome data, although it did not disclose the size of that dataset or provide external validation metrics in the announcement.

The market signal is straightforward: women’s health startups are still finding capital when they pair a specific clinical problem with infrastructure that could support diagnostics, research partnerships and care delivery. Juno Bio’s bet is that owning the lab gives it more control over quality, turnaround and product development than relying on third-party sequencing capacity.

The company also said about half of its users experience co-infections, which it says are often missed by conventional testing and can affect treatment outcomes. It did not provide peer-reviewed outcome data in the announcement showing how its testing changes diagnosis rates, prescribing decisions or patient outcomes at scale.

For investors, the question is whether Juno Bio can turn a test with consumer traction into a defensible clinical diagnostics business. The new lab and funding give the company more operating capacity, but reimbursement, clinician adoption and evidence generation will determine whether vaginal microbiome testing becomes routine care or remains a specialist and self-pay category.

This story draws on original reporting from Tech.eu.